image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 95.45
4.98 %
$ 6.54 B
Market Cap
21.89
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LNTH stock under the worst case scenario is HIDDEN Compared to the current market price of 95.5 USD, Lantheus Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LNTH stock under the base case scenario is HIDDEN Compared to the current market price of 95.5 USD, Lantheus Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LNTH stock under the best case scenario is HIDDEN Compared to the current market price of 95.5 USD, Lantheus Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LNTH

image
$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.53 B REVENUE
18.32%
457 M OPERATING INCOME
25.32%
312 M NET INCOME
-4.35%
545 M OPERATING CASH FLOW
78.45%
-226 M INVESTING CASH FLOW
-3805.61%
-119 M FINANCING CASH FLOW
-807.49%
391 M REVENUE
3.27%
114 M OPERATING INCOME
-14.86%
-11.8 M NET INCOME
0.00%
158 M OPERATING CASH FLOW
-9.90%
-6.6 M INVESTING CASH FLOW
90.26%
-104 M FINANCING CASH FLOW
-5546.23%
Balance Sheet Lantheus Holdings, Inc.
image
Current Assets 1.33 B
Cash & Short-Term Investments 913 M
Receivables 321 M
Other Current Assets 92.6 M
Non-Current Assets 654 M
Long-Term Investments 39.5 M
PP&E 177 M
Other Non-Current Assets 437 M
46.09 %16.22 %4.67 %8.93 %22.09 %Total Assets$2.0b
Current Liabilities 241 M
Accounts Payable 34.6 M
Short-Term Debt 974 K
Other Current Liabilities 205 M
Non-Current Liabilities 652 M
Long-Term Debt 0
Other Non-Current Liabilities 652 M
3.87 %22.97 %73.05 %Total Liabilities$892.3m
EFFICIENCY
Earnings Waterfall Lantheus Holdings, Inc.
image
Revenue 1.53 B
Cost Of Revenue 546 M
Gross Profit 988 M
Operating Expenses 531 M
Operating Income 457 M
Other Expenses 145 M
Net Income 312 M
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m002b(546m)988m(531m)457m(145m)312mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
64.43% GROSS MARGIN
64.43%
29.79% OPERATING MARGIN
29.79%
20.37% NET MARGIN
20.37%
28.72% ROE
28.72%
15.78% ROA
15.78%
19.03% ROIC
19.03%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lantheus Holdings, Inc.
image
500m500m450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 312 M
Depreciation & Amortization 64.6 M
Capital Expenditures -51.6 M
Stock-Based Compensation 76.4 M
Change in Working Capital 2.05 M
Others 165 M
Free Cash Flow 493 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lantheus Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for LNTH of $152 , with forecasts ranging from a low of $125 to a high of $175 .
LNTH Lowest Price Target Wall Street Target
125 USD 30.96%
LNTH Average Price Target Wall Street Target
152 USD 59.25%
LNTH Highest Price Target Wall Street Target
175 USD 83.34%
Price
Max Price Target
Min Price Target
Average Price Target
18018016016014014012012010010080806060May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Lantheus Holdings, Inc.
image
Sold
0-3 MONTHS
6.22 M USD 3
3-6 MONTHS
2.07 M USD 4
6-9 MONTHS
3.03 M USD 5
9-12 MONTHS
4.31 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Lantheus Completes Acquisition of Evergreen Theragnostics BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. (“Evergreen”), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025. globenewswire.com - 2 weeks ago
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics. Pylarify's potential patent expiration in 2026 poses a risk, but management is actively seeking to extend protections and diversify revenue streams. seekingalpha.com - 1 month ago
Lantheus' Pylarify Hit $1B in 2024 Sales Lantheus Holdings (LNTH -1.07%) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions. fool.com - 1 month ago
Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q4 2024 - Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Amanda Morgan - Chief Commercial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities Paul Choi - Goldman Sachs Matt Taylor - Jefferies Yuan Zhi - B. Riley Larry Solow - CJS Securities Justin Walsh - Jones Trading Andy Hsieh - William Blair John Vandermosten - Zacks Kemp Dolliver - Brookline Capital Markets David Turkaly - Citizens JMP Operator Good morning. seekingalpha.com - 1 month ago
Lantheus (LNTH): A 10x Opportunity in Radiopharmaceuticals Explore the exciting world of Lantheus Holdings (LNTH 1.39%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! fool.com - 1 month ago
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D. BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus' strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent. globenewswire.com - 2 months ago
Why Lantheus Holdings Stock Got Thrashed on Tuesday Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day. fool.com - 2 months ago
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent , PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January 28, 2025, at 8:30 AM ET BEDFORD, Mass. , Jan. 28, 2025 /PRNewswire/ -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen"), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments. prnewswire.com - 2 months ago
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities globenewswire.com - 2 months ago
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease globenewswire.com - 3 months ago
Lantheus Holdings: Powerhouse Potential In 2025 Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, is projected to reach $2.5 billion by 2030, driven by its superior PSMA PET imaging technology. DEFINITY holds an 80% market share in ultrasound imaging, with the market expected to nearly double, further solidifying Lantheus' financial stability. seekingalpha.com - 3 months ago
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia SYDNEY, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has entered into a strategic co-development partnership with Lantheus to advance the clinical development of innovative radiopharmaceuticals in Australia. globenewswire.com - 3 months ago
8. Profile Summary

Lantheus Holdings, Inc. LNTH

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 6.54 B
Dividend Yield 0.00%
Description Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Contact 331 Treble Cove Road, North Billerica, MA, 01862 https://www.lantheus.com
IPO Date June 25, 2015
Employees 808
Officers Mr. Paul M. Blanchfield President Ms. Linda S. Lennox Vice President of Corporate Communications & Chief of Staff Ms. Amanda M. Morgan Chief Commercial Officer Dr. Jean-Claude Provost M.D. Chief Science Officer Mr. Brian A. Markison Chief Executive Officer & Director Mr. Robert J. Marshall Jr., CFA Chief Financial Officer & Treasurer Mr. Daniel M. Niedzwiecki Chief Administrative Officer, General Counsel & Corporate Secretary Ms. Dorothy Barr Senior Vice President of Manufacturing & Technical Operations Ms. Lee Anne Howe Chief Information Officer Ms. Jamie Spaeth Chief People Officer